Your browser doesn't support javascript.
loading
[The Usher Syndrome, a Human Ciliopathy]. / Das Usher-Syndrom, eine Ziliopathie des Menschen.
Wolfrum, Uwe; Nagel-Wolfrum, Kerstin.
Affiliation
  • Wolfrum U; Institut für Molekulare Physiologie, Johannes Gutenberg-Universität, Mainz.
  • Nagel-Wolfrum K; Institut für Molekulare Physiologie, Johannes Gutenberg-Universität, Mainz.
Klin Monbl Augenheilkd ; 235(3): 273-280, 2018 Mar.
Article in De | MEDLINE | ID: mdl-29534264
ABSTRACT
The human Usher syndrome (USH) is a complex, rare disease manifesting in its most common form of inherited deaf-blindness. Due to the heterogeneous manifestation of the clinical symptoms, three clinical types (USH1-3) are distinguished according to the severity of the disease pattern. For a correct diagnosis, in addition to the auditory tests in early newborn screening, ophthalmological examinations and molecular genetic analysis are important. Ten known USH genes encode proteins, which are from heterogeneous protein families, interact in functional protein networks. In the eye and in the ear, USH proteins are expressed primarily in the mechano-sensitive hair cells and the rod and cone photoreceptor cells, respectively. In the hair cells, the USH protein networks are essential for the correct differentiation of the hair bundles as well as for the function of the mechano-electrical transduction complex in the matured cell. In the photoreceptor cells, USH proteins are located in the ciliary region and participate in intracellular transport processes. In addition, a USH protein network is present in the so-called calyceal processes. The lack of calyceal processes and the absence of a prominent visual phenotype in the mouse disqualifies mice as models for studies on the ophthalmic component of USH. While hearing impairments can be compensated with hearing aids and cochlear implants, there is no practical therapy for USH in the eye. Currently, gene-based therapy concepts, such as gene addition, applications of antisense oligonucleotides and TRIDs ("translational readthrough inducing drugs") for the readthrough of nonsense mutations are preclinically evaluated. For USH1B/MYO7A the UshStat gene therapy clinical trial is ongoing.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rare Diseases / Usher Syndromes / Ciliopathies Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Female / Humans / Newborn / Pregnancy Language: De Journal: Klin Monbl Augenheilkd Year: 2018 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rare Diseases / Usher Syndromes / Ciliopathies Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Female / Humans / Newborn / Pregnancy Language: De Journal: Klin Monbl Augenheilkd Year: 2018 Document type: Article